Ministry of Industry and explained what restrictions affect foreign PM
Print
15 September 2014
Market Access Solutions
Ministry of Industry and Trade has explained its position on foreign medicines, whose participation in the public procurement plan to cap. Developed a draft resolution will help the Ministry of Industry in 2018 90% of the domestic market to provide domestic medicines.
According to the ministry, the priority will be given to the Russian pharmaceutical manufacturers only in public procurement, and the foreign companies will not be permitted to participate in the tenders. Especially if the foreign manufacturer is the sole supplier of the drug.
"In the priority for Industry and Trade - the welfare of citizens of Russia and provide all the necessary drugs. The proposed measures can not cause a shortage of medicines, as prepared in advance, based on the needs of consumers and opportunities for our producers. Provided the necessary volume of domestic production. Restriction will be valid only if the Russian one and the same drug release at least two Russian producer, "- said the Minister of Industry and Trade Denis Manturov.
In addition, on a par with domestic companies in the auction will be participating manufacturers from countries of the Customs Union. In this case, if the foreign company has built a pharmaceutical plant in Russia, Belarus and Kazakhstan, it will also be considered as domestic production.
With regard to the implementation of foreign drugs in pharmacies, the Industry and Trade Ministry has no plans to limit her - the consumer will always choose between Russian and foreign medicine. Also, if there are medical indications imported medicine may be purchased individually for the patient to address the medical commission.
All Portfolio
MEDIA CENTER
-
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.